R&D
C4U and Sumitomo Dainippon Pharma enter into the Next Stage of Joint Research
C4U and Sumitomo Dainippon Pharma have entered into the next stage of the joint research aiming the medical application of CRISPR-Cas3 by specifying the target gene and cell in the field of the central nervous system diseases. This progress has been made based on our joint research which was announced on August 3, 2021.